title: Granulocyte colony-stimulating factor (G-CSF) administration in individuals with sickle cell disease: time for a moratorium?
abstract: Granulocyte colony-stimulating factor (G-CSF) is used commonly in an attempt to reduce the duration of neutropenia and hospitalization in patients undergoing chemotherapy and to obtain hematopoietic stem cells (HSC) for transplantation applications. Despite the relative safety of administration of G-CSF in most individuals, including subjects with sickle cell trait, severe and life-threatening complications have been reported when used in individuals with sickle cell disease (SCD), including those who were asymptomatic and undiagnosed prior to administration. The administration of G-CSF has now been reported in a total of 11 individuals with SCD. Seven developed severe adverse events, including vaso-occlusive episodes, acute chest syndrome, multi-organ system failure and death. Precautions, including minimizing the peak white blood cell count, dividing or reducing the G-CSF dose and red blood cell transfusions to reduce sickle hemoglobin (HbS) levels, have been employed with no consistent benefit. These reported data indicate that administration of G-CSF in individuals with SCD should be undertaken only in the absence of alternatives and after full disclosure of the risks involved. Unless further data demonstrate safety, routine usage of G-CSF in individuals with SCD should be avoided.
authors.affiliation: Molecular and Clinical Hematology Branch, National Institute of Diabetes, Digestive and Kidney Diseases and National Heart, Lung and Blood Institute, National Institutes of Health, NIH, Bethesda, Maryland, USA.
authors.forename: Courtney D
authors.initials: CD
authors.lastname: Fitzhugh
authors.forename: Matthew M
authors.initials: MM
authors.lastname: Hsieh
authors.forename: Charles D
authors.initials: CD
authors.lastname: Bolan
authors.forename: Carla
authors.initials: C
authors.lastname: Saenz
authors.forename: John F
authors.initials: JF
authors.lastname: Tisdale
mesh_terms: D000755:Anemia, Sickle Cell / Q000150:complications / Q000188:drug therapy*; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D018570:Risk Assessment; D013997:Time Factors
chemical_list: D016179:Granulocyte Colony-Stimulating Factor